PHARMING GROUP NV (PHARM.AS) Forecast, Price Target & Analyst Ratings

AMS:PHARM • NL0010391025

Current stock price

1.423 EUR
+0 (+0.07%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHARMING GROUP NV (PHARM.AS).

Forecast Snapshot

Consensus Price Target

Price Target
€2.19
+ 54.11% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
$0.00
Revenue Estimate
96.563M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
88.57%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€2.19
Upside
+ 54.11%
From current price of €1.42 to mean target of €2.19, Based on 14 analyst forecasts
Low
€1.82
Median
€2.04
High
€2.73

Price Target Revisions

1 Month
0.00%
3 Months
9.14%

Price Target Summary

14 Wall Street analysts provided a forecast for the next 12 months for PHARM.AS. The average price target is 2.19 EUR. This implies a price increase of 54.11% is expected in the next year compared to the current price of 1.423.
The average price target has been revised upward by 9.14% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

PHARM Current Analyst RatingPHARM Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

PHARM Historical Analyst RatingsPHARM Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
88.57%
PHARM.AS was analyzed by 14 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about PHARM.AS.
In the previous month the buy percentage consensus was at a similar level.
PHARM.AS was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
$0.00
Revenue Estimate
96.563M
Revenue Q2Q
22.09%
EPS Q2Q
107.02%
Number of Analysts
5

Next Earnings Revisions

Revenue (1 Month)
0.81%
Revenue (3 Months)
0.81%
EPS (1 Month)
-95.00%
EPS (3 Months)
-95.00%

Next Earnings Summary

PHARM.AS is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is 0 EUR and the consensus revenue estimate is 96.56M EUR.
The next earnings revenue estimate has been revised upward by 0.81% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2031

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
PHARM.AS revenue by date.PHARM.AS revenue by date.
245.316M
19.30%		297.2M
21.15%		376.134M
26.56%		413.89M
10.04%		425.05M
2.70%		403.89M
-4.98%		488.21M
20.88%		687.27M
40.77%		485.44M
-29.37%
EBITDA
YoY % growth
PHARM.AS ebitda by date.PHARM.AS ebitda by date.
-5.825M
-124.73%		12.476M
314.18%		43.458M
248.33%		25.209M
-41.99%		31.879M
26.46%		78.826M
147.27%		134.3M
70.38%		235.66M
75.47%		N/A
EBIT
YoY % growth
PHARM.AS ebit by date.PHARM.AS ebit by date.
-21.75M
-309.80%		-3.594M
83.48%		32.242M
997.11%		32.497M
0.79%		34.68M
6.72%		36.256M
4.54%		84.367M
132.70%		234.62M
178.09%		42.453M
-81.91%
Operating Margin
PHARM.AS operating margin by date.PHARM.AS operating margin by date.
-8.87%-1.21%8.57%7.85%8.16%8.98%17.28%34.14%8.75%
EPS
YoY % growth
PHARM.AS eps by date.PHARM.AS eps by date.
-0.02
-132.92%		-0.02
-12.50%		0.00
111.11%		0.04
1,877.60%		0.04
-6.77%		0.06
66.48%		0.12
88.42%		0.22
94.12%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		0.00
107.02%		0.02
243.33%		0.01
3.00%		0.01
28.75%
Revenue
Q2Q % growth		96.563M
22.09%		92.185M
-1.09%		89.61M
-7.90%		88.58M
-16.85%
EBITDA
Q2Q % growth		6.18M
85.14%		N/AN/AN/A
EBIT
Q2Q % growth		3.09M
308.73%		10.197M
-21.25%		7.21M
-55.00%		4.017M
67.38%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
213.10%
EPS Next 5 Year
157.07%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
2.04%
Revenue Next 5 Year
12.57%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
48.37%
EBIT Next 5 Year
57.73%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

PHARMING GROUP NV / PHARM.AS Forecast FAQ

What is the average price target for PHARMING GROUP NV (PHARM.AS) stock?

14 analysts have analysed PHARM.AS and the average price target is 2.19 EUR. This implies a price increase of 54.11% is expected in the next year compared to the current price of 1.423.

What is the next earnings date for PHARM stock?

PHARMING GROUP NV (PHARM.AS) will report earnings on 2026-05-07.

Can you provide the consensus estimates for PHARMING GROUP NV next earnings?

The consensus EPS estimate for the next earnings of PHARMING GROUP NV (PHARM.AS) is 0 EUR and the consensus revenue estimate is 96.56M EUR.

What is the consensus rating for PHARMING GROUP NV (PHARM.AS) stock?

The consensus rating for PHARMING GROUP NV (PHARM.AS) is 88.5714 / 100 . This indicates that analysts generally have a positive outlook on the stock.